

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

SYNTHEGO CORPORATION,¹

Debtor.

Chapter 11

Case No. 25-10823 (MFW)

Ref. Docket No. 134

CERTIFICATE OF SERVICE

I, ANDREA SPEELMAN, hereby certify that:

1. I am employed as a Case Manager by Epiq Corporate Restructuring, LLC, with their principal office located at 777 Third Avenue, New York, New York 10017. I am over the age of eighteen years and am not a party to the above-captioned action.
2. On June 6, 2025, I caused to be served the:
 - a. "Notice of Potential Assumption, Assumption and Assignment, or Transfer of Executory Contracts and Unexpired Leases," dated June 6, 2025 [Docket No. 134], (the "Assumption Notice"), and
 - b. *customized* "Notice of Potential Assumption, Assumption and Assignment, or Transfer of Executory Contracts and Unexpired Leases," dated June 6, 2025, *related to Docket No. 134*, a sample of which is annexed hereto as Exhibit A, (the "Custom Notice"),

by causing true and correct copies of the:

- i. Assumption Notice to be enclosed securely in separate postage pre-paid envelopes and delivered via first class mail to those parties listed on the annexed Exhibit B,
- ii. Custom Notice to be enclosed securely in separate postage pre-paid envelopes and delivered via first class mail to those parties listed on the annexed Exhibit C, and
- iii. Assumption Notice to be delivered via electronic mail to those parties listed on the annexed Exhibit D.

¹ The Debtor's mailing address is 3696 Haven Avenue, Suite A, Redwood City, California, 94063, and the last four digits of the Debtor's federal tax identification number is 9518.

3. All envelopes utilized in the service of the foregoing contained the following legend:
“LEGAL DOCUMENTS ENCLOSED. PLEASE DIRECT TO THE ATTENTION OF ADDRESSEE, PRESIDENT, OR LEGAL DEPARTMENT.”

/s/ Andrea Speelman
Andrea Speelman

EXHIBIT A

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:

SYNTHEGO CORPORATION,¹

Debtor.

Chapter 11

Case No. 25-10823 (MFW)

**NOTICE OF POTENTIAL ASSUMPTION, ASSUMPTION AND ASSIGNMENT,
OR TRANSFER OF EXECUTORY CONTRACTS AND UNEXPIRED LEASES**

PLEASE TAKE NOTICE OF THE FOLLOWING:

On May 5, 2025 (the “Petition Date”), the above-captioned debtor and debtor in possession (the “Debtor”) filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”). The Debtor is operating its business and managing its property as debtor in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.²

On May 29, 2025, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order (the “Bid Procedures Order”³) authorizing the Debtor to establish procedures related to, among other things, the assumption, assumption and assignment, and/or transfer of executory contracts and unexpired leases in connection with a sale of substantially all of the Debtor’s assets to be approved by the Court (the “Contract and Lease Procedures”).

YOU ARE RECEIVING THIS NOTICE BECAUSE YOU ARE A PARTY TO ONE OR MORE OF THE CONTRACTS OR LEASES REFERRED TO HEREIN.

¹ The Debtor’s mailing address is 3696 Haven Avenue, Suite A, Redwood City, California, 94063, and the last four digits of the Debtor’s federal tax identification number is 9518.

² Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the *Motion for (I) An Order (A) Authorizing Entry Into Asset Purchase Agreement With Respect to the Sale of Substantially All of the Debtor’s Assets, (B) Approving Bid Procedures for the Sale of Substantially All of the Debtor’s Assets, (C) Scheduling an Auction and Sale Hearing, (D) Approving the Form and Manner of Notice Thereof, (E) Approving Certain Termination Fee and Expense Reimbursement Provisions, and (F) Granting Related Relief; and (II) An Order (A) Approving the Sale of the Debtor’s Assets Free and Clear of All Encumbrances, (B) Approving the Assumption and Assignment of Executory Contracts and Unexpired Leases, and (C) Granting Related Relief* [Docket No. 12] (the “Bid Procedures Motion”) or Bid Procedures Order (defined below).

³ *Order (A) Authorizing Entry Into Asset Purchase Agreement With Respect to the Sale of Substantially All of the Debtor’s Assets, (B) Approving Bid Procedures for the Sale of Substantially All of the Debtor’s Assets, (C) Scheduling an Auction and Sale Hearing, (D) Approving the Form and Manner of Notice Thereof, (E) Approving Certain Termination Fee and Expense Reimbursement Provisions, and (F) Granting Related Relief* [Docket No. 97] (the “Bid Procedures Order”).

POTENTIAL ASSUMED/ASSIGNED CONTRACTS⁴

Attached as Schedule A is a schedule of all Potential Assumed/Assigned Contracts (the “Cure Schedule”) that may be assumed, assumed and assigned, and/or transferred, as applicable, by the Debtor in connection with the Sale, listing the counterparties to such contracts (the “Contract Counterparties”) and the amount, if any, proposed to be paid to cure any monetary defaults under the Potential Assumed/Assigned Contracts pursuant to section 365 of the Bankruptcy Code (the “Cure Amounts”).⁵ **The inclusion of a document on the Cure Schedule is not a commitment that such Potential Assumed/Assigned Contract will, in fact, be assumed by the Debtor, assumed by the Debtor and assigned to a third party, or otherwise transferred by the Debtor to a third party, including in connection with the Sale. The identification of any executory contract or unexpired lease as one that, in connection with a Sale, will, in fact, be assumed by the Debtor, assumed by the Debtor and assigned to a third party, or otherwise transferred to a third party are governed by the Bid Procedures Order.**

IF YOU AGREE WITH THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR TRANSFER OF YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S) AND/OR PROPOSED CURE AMOUNTS LISTED IN SCHEDULE A WITH RESPECT TO YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S), YOU ARE NOT REQUIRED TO TAKE ANY FURTHER ACTION.

IF YOU DISAGREE WITH THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR TRANSFER OF YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S) AND/OR THE PROPOSED CURE AMOUNTS LISTED IN SCHEDULE A WITH RESPECT TO YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S), YOU MUST OBJECT BY NO LATER THAN **JUNE 20, 2025 AT 5:00 P.M. (PREVAILING EASTERN TIME)** (the “Contract Objection Deadline”).

Objections with respect to any Potential Assumed/Assigned Contracts (a “Contract Objection”) must be: (i) made in writing and filed on the docket for the Chapter 11 Case no later than the Contract Objection Deadline; (ii) state the basis of such Contract Objection with specificity, including, without limitation, the Cure Amount alleged to be due to such Contract Counterparty, and include complete contact information for such Contract Counterparty (including address, telephone number, and email address); (iii) comply with the Bankruptcy Code, the Bankruptcy Rules, and the Local Rules, and (iv) be served on the following, so as to be actually received by them on or before the Contract Objection Deadline (collectively, the “Notice Parties”):

- i. counsel for the Debtor, (a) Fenwick & West, LLP, 902 Broadway, 18th Floor, New York, NY 10010, Attn: Ethan Skerry (eskerry@fenwick.com), and Brendan Montgomery (bmontgomery@fenwick.com); (b) Pachulski Stang Ziehl & Jones LLP, 919 North Market Street, 17th Floor, P.O. Box 8705, Wilmington, DE 19899-8705

⁴ The presence of any contract or lease on Schedule A hereto does not constitute an admission that such contract or lease is an executory contract or unexpired lease within the meaning of section 365 of the Bankruptcy Code or that such contract or lease will be assumed and/or assigned by the Debtor.

⁵ For avoidance of doubt, the Debtor reserves all rights to remove any executory contract or unexpired lease from the Cure Schedule prior to closing of any sale.

(Courier 19801), Attn: James E. O'Neill (joneill@pszjlaw.com); and (c) Pachulski Stang Ziehl & Jones LLP, One Sansome Street, Suite 3430, San Francisco, CA 94104, Attn: Debra I. Grassgreen (dgrassgreen@pszjlaw.com) and Maxim B. Litvak (mlitvak@pszjlaw.com);

- ii. counsel to the Stalking Horse Bidder, (a) Morrison & Foerster LLP, 250 West 55th Street, Floor 20, New York, NY 10019, Attn: James A. Newton, Esq. (jnewton@mof.com) and Miranda K. Russell, Esq. (mrussell@mof.com); and (b) Potter Anderson & Corroon LLP, Attn: Christopher M. Samis (csamis@potteranderson.com) and Brett M. Haywood (bhaywood@potteranderson.com);
- iii. counsel to the Committee, if any; and
- iv. the Office of The United States Trustee, 844 King Street, Suite 2207, Lockbox 35, Wilmington, DE 19801, Attn: Megan Seliber (megan.seliber@usdoj.gov).

Any Contract Counterparty that objects to a Successful Bidder's provision of additional assurance of future performance (the "Adequate Assurance Objection") must file such Adequate Assurance Objection on or before the Sale Hearing and serve such objection on the Notice Parties and the applicable Successful Bidder, or such objecting party may appear and argue at the Sale Hearing. To the extent the parties are unable to resolve an Adequate Assurance Objection, the Court will set a hearing, which may be at the Sale Hearing, on the Adequate Assurance Objection to determine whether terms of the Successful Bid are compliant with section 365 of the Bankruptcy Code in providing adequate assurance of future performance to the Contract Counterparty of the applicable contract or lease.

If you file a Cure Objection or Assumption/Assignment Objection satisfying the requirements herein, the Debtor will confer with you in good faith to attempt to resolve any such Cure Objection or Assumption/Assignment Objection without Bankruptcy Court intervention. If the applicable parties determine that the Cure Objection or Assumption/Assignment Objection cannot be resolved without judicial intervention in a timely manner, the Bankruptcy Court shall resolve such objections (i) at the Sale Hearing scheduled for **June 27, 2025 at 2:00 p.m. (prevailing Eastern Time)** via Zoom and at the United States Bankruptcy Court for the District of Delaware, United States Courthouse, 824 Market Street North, 5th Floor, Courtroom #4, Wilmington, DE 19801, before the Honorable Mary F. Walrath, United States Bankruptcy Judge, or (ii) on such other date subsequent to a Sale Hearing as the Court may designate prior to, during, or after the Sale Hearing (a "Contract Hearing") before the Bankruptcy Court to consider the objection.

If the Debtor identifies additional executory contracts or unexpired leases that it wishes to add to or remove from the Cure Schedule (each an "Additional Contract"), the Debtor shall, as soon as practicable after making such a determination, send an Additional Cure Notice to the applicable Contract Counterparties to such Additional Contracts. To the extent an executory contract or unexpired lease is not assumed, assumed and assigned, or transferred in connection with a Sale, the Debtor may, in its sole discretion, reject such an executory contract or unexpired lease to the extent permitted by law following the Closing.

Objections from any Contract Counterparty to an Additional Contract (an “Additional Contract Objection”) must: (i) be made in writing and filed on the docket by the later of (a) the Contract Objection Deadline and (b) seven (7) calendar days after the Debtor files and serves the Additional Cure Notice (as applicable, the “Additional Contract Objection Deadline”); (ii) state the basis of such objection with specificity, including, without limitation, the Cure Amount alleged by such Contract Counterparty, and include contact information for such Contract Counterparty; (iii) comply with the Bankruptcy Code, the Bankruptcy Rules, and the Local Rules; and (iv) be served upon the Notice Parties so as to be actually received by them on or before the Additional Contract Objection Deadline.

If a timely Additional Contract Objection is filed, and cannot be resolved consensually, the Bankruptcy Court shall resolve such Additional Potential Assignment Objection at a hearing to be held (i) on or before seven (7) calendar days from the timely filing of the Additional Potential Assignment Objection; (ii) at the Sale Hearing; or (iii) such other date designated by the Court.

IF YOU FAIL TO TIMELY FILE AND PROPERLY SERVE A CURE OBJECTION OR ASSUMPTION/ASSIGNMENT OBJECTION AS PROVIDED HEREIN (I) YOU WILL BE DEEMED TO HAVE FOREVER WAIVED AND RELEASED ANY RIGHT TO ASSERT A CURE OBJECTION, ASSUMPTION/ASSIGNMENT OBJECTION, OR ADDITIONAL CONTRACT OBJECTION, AS APPLICABLE, AND TO HAVE OTHERWISE CONSENTED TO THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR SALE AND TRANSFER, OF THE DEBTOR’S RIGHT, TITLE, AND INTEREST IN, TO AND UNDER, SUCH POTENTIAL ASSUMED/ASSIGNED CONTRACT OR ADDITIONAL CONTRACT, AS APPLICABLE, ON THE TERMS SET FORTH IN THIS CURE NOTICE AND THE APPLICABLE PURCHASE AGREEMENT, (II) YOU WILL HAVE CONSENTED TO THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT OF, OR SALE AND TRANSFER OF, THE DEBTOR’S RIGHT, TITLE, AND INTEREST IN, TO AND UNDER, ITS POTENTIAL ASSUMED/ASSIGNED CONTRACT, AS THE CASE MAY BE, WITHOUT THE NECESSITY OF OBTAINING ANY FURTHER ORDER OF THE BANKRUPTCY COURT, AND (III) YOU WILL BE BARRED AND ESTOPPED FOREVER FROM ASSERTING OR CLAIMING AGAINST ANY PARTY THAT ANY ADDITIONAL CURE AMOUNTS ARE DUE OR DEFAULTS EXIST, OR CONDITIONS TO ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR SALE AND TRANSFER, MUST BE SATISFIED, UNDER SUCH POTENTIAL ASSUMED/ASSIGNED CONTRACT.

The Debtor’s assumption, assumption and assignment, or sale and transfer, of a Potential Assumed/Assigned Contract is subject to approval by the Bankruptcy Court and consummation of the closing of a Sale. The inclusion of any document on the list of Potential Assumed/Assigned Contracts shall not constitute or be deemed to be a determination or admission by the Debtor that such document is, in fact, an executory contract or unexpired lease within the meaning of the Bankruptcy Code, and all rights with respect thereto are expressly reserved.

The dates set forth in this notice are subject to change, and further notice of such changes may not be provided except through announcements in open court and/or the filing of notices and/or amended agendas. Parties in interest are encouraged to monitor the electronic court docket available at <https://dm.epiq11.com/case/synthego/info>.

This Notice is subject to the full terms and conditions of the Bid Procedures Order, which shall control in the event of any conflict. The Debtor encourages parties in interest to review such documents in their entirety and consult an attorney if they have questions or want advice.

Dated: June 6, 2025

PACHULSKI STANG ZIEHL & JONES LLP

/s/ James E. O'Neill

Debra I. Grassgreen (admitted *pro hac vice*)

Maxim B. Litvak (admitted *pro hac vice*)

Malhar S. Pagay (admitted *pro hac vice*)

James E. O'Neill (DE Bar No. 4042)

919 North Market Street, 17th Floor

P.O. Box 8750

Wilmington, Delaware 19899-8705

Tel: 302-652-4100

Fax: 302-652-4400

Email: dgrassgreen@pszjlaw.com

mlitvak@pszjlaw.com

mpagay@pszjlaw.com

joneill@pszjlaw.com

Counsel to the Debtor and Debtor in Possession

Schedule A

Schedule of Potential Assumed/Assigned Contracts

No.	Contract Counterparty	Contract/Lease Title	Date of Contract/Lease	Cure Amount
57	DECODE SCIENCES PTY LTD.	DISTRIBUTOR AGREEMENT	2025-02-14	\$0.00

EXHIBIT B

Name	Address
DISTRICT OF DELAWARE - S. T. HANSON	HERCULES BUILDING US ATTORNEYS OFFICE 1313 N. MARKET ST, PO BOX 2046 WILMINGTON DE 19801
INTERNAL REVENUE SERVICE	P.O. BOX 7346 PHILADELPHIA PA 19101-7346

Total Count: 2

EXHIBIT C

Name	Address
23ANDME, INC.	223 NORTH MATHILDA AVENUE SUNNYDALE CA 94086
4BASEIO UK, LTD.	25 NORMAN WAY OVER C24 5QE UNITED KINGDOM
955 CHARTER PARTNERS	2596 BAY ROAD SUITE A REDWOOD CITY CA 94063
ABBVIE, INC.	1 N WAUKEGAN ROAD NORTH CHICAGO IL 60064
ADAPTIMMUNE LIMITED	60 JUBILEE AVENUE MILTON PARK ABBINGDON OXFORDSHIRE OX14 4RX UNITED KINGDOM
AKRON BIOMANUFACTURING, LLC	600 TALLEVAST ROAD SUITE 201 SARASOTA FL 34243
ANDERSON TAX LLC	1200 FIFTH AVENUE SUITE 1600 SEATTLE WA 98101
ANGELA SUMMERS	ADDRESS ON FILE
ARSENAL BIOSCIENCES, INC.	2 TOWER PLACE SUITE 700 SOUTH SAN FRANCISCO CA 94080
ARSENALBIO	2 TOWER PL SUITE 600 SOUTH SAN FRANCISCO CA 94080
ASPEN NEUROSCIENCE, INC.	10835 ROAD TO THE CURE SUITE 100 SAN DIEGO CA 92121
ASTRAZENECA PHARMACEUTICALS LP	1800 CONCORD PIKE WILMINGTON DE 19897
ASTRAZENECA UK LIMITED	1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE CB2 0AA UNITED KINGDOM
AVANCE BIOSCIENCES, INC.	9770 W LITTLE YORK HOUSTON TX 77040
BARTON INTEGRATION LLC	5151 CALIFORNIA SUITE 100 IRVINE CA 92617
BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLAZA HOUSTON TX 77030
BEAM CONSULTING COMPANY	814 NORTH PACIFIC STREET OCEANSIDE CA 92054
BECKMAN RESEARCH INSTITUTE OF	THE CITY OF HOPE 1500 E DUARTE RD ROOM 3344 DUARTE CA 91010
BEIGENE (TAIWAN) LIMITED	NANJING E. RD TAIPEI CITY 114030 TAIWAN
BEIJING TEE & HOWE LAW OFFICE	10TH FLOOR TOWER D MINSHENG FINANCIAL CENTER 28 JIANGUOMENNEI AVE BEIJING 100005 CHINA
BIOLEGIO B.V.	LAGELANDSEWEG 56 6545CG NIJMEGEN NETHERLANDS
BIO-MEDICAL SCIENCE CO., LTD.	22 YEOKSAM-RO 7-GIL GANGNAM-GU SEOUL 06244 SOUTH KOREA
BIT BIO LIMITED	DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS CAMBRIDGE CB22 3FH UNITED KINGDOM
BIT.BIO LTD.	TH DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS CAMBRIDGE CB22 3FH UNITED KINGDOM
BLUEPRINT MEDECINES CORPORATION	45 SIDNEY STREET CAMBRIDGE MA 02139
BLUEROCK THERAPEUTICS LP	ONE BROADWAY 15TH FLOOR CAMBRIDGE MA 02412
BLUESPHERE BIO	100 TECHNOLOGY DRIVE SUITE 526 PITTSBURGH PA 15219
BOARD OF REGENTS OF THE UNIVERSITY OF	OKLAHOMA 865 RESEARCH PARKWAY OKLAHOMA CITY OK 73104
BODNER FLOM LAW OFFICES	65 YIGAL ALON STREET TEL AVIV 67443 ISRAEL
CALIFORNIA INSTITUTE FOR REGENERATIVE	MEDICINE 601 GATEWAY BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080
CARTHERICS PTY LTD	MONASH HEALTH TRANSLATION PRECINCT HUDSON INSTITUTE FOR MEDICAL RESEARCH 27-31 WRIGHT STREET CLAYTON VIC 3168 AUSTRALIA
CELULARITY INC.	170 PARK AVE FLORHAM PARK NJ 7932
CHARITE	CHARITÉ UNIVERSITAETSMEDIZIN BERLIN BERLIN DE 13353 GERMANY
CHENGDU UCELLO BIOTECHNOLOGY CO. LIMITED	BUILDING D1 TIANFU INTERNATIONAL BIO-TOWN SHUANGLIU DISTRICT 2ND FLOOR CHENGDU 610200 CHINA
CHILDRENS GMP, LLC	262 DANNY THOMAS PLACE MEMPHIS TN 38105
CHILI PIPER, INC.	3696 HAVEN AVENUE SUITE A REDWOOD CITY CA 94063
CITY OF HOPE	1500 E DUARTE RD RM 3344 DUARTE CA 91010
CLARI, INC.	1154 SONORA COURT SUNNYVALE CA 94086
CLOUDFLARE	101 TOWNSEND STREET SAN FRANCISCO CA 94107
CONFIG CONSULTANTS, LLC	4900 HOPYARD ROAD SUITE 100 PLEASANTON CA 94588
CONTENTSTACK INC.	49 GEARY ST. SUITE 238 SAN FRANCISCO CA 94108
CORPORATE VISIONS, INC.	5455 KIETZKE LANE RENO NV 89511
CORRGENE BIOTECHNOLOGY CO., LTD.	CHANGFA INTERNATIONAL PRECISION MEDICINE ACCELERATION CENTER NO .21 CHANGPING DISTRICT BEIJING CHINA
CRISPR THERAPEUTICS	200 SIDNEY ST CAMBRIDGE MA 02139

Name	Address
CRISPR THERAPEUTICS, INC.	610 MAIN STREET NORTH BUILDING CAMBRIDGE MA 02139
DAKEWE BIOTECH CO., LTD.	RM 203 UNIT A NANSHAN DISTRICT SHENZHEN 518067 CHINA
DECODE SCIENCES PTY LTD.	3/247 FERNTREE GULLY ROAD MOUNT WAVERLY VIC 3149 AUSTRALIA
DEGREE, INC (DBA LATTICE)	360 SPEAR ST FLOOR 4 SAN FRANCISCO CA 94105
DICE THERAPEUTICS, INC.	400 EAST JAMIE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080
EDITCO BIO, INC.	600 SAGINAW DRIVE REDWOOD CITY CA 94063
EGGLI PROPERTIES	3585 HAVEN AVENUE SUITE G MENLO PARK CA 94025
ELEMENT MATERIALS TECHNOLOGY	PHARMA US LLC 9240 SANTA FE SPRINGS ROAD SANTA FE SPRINGS CA 90670
EMD MILLIPORE	400 SUMMIT DRIVE BURLINGTON MA 01803
EMORY UNIVERSITY	1599 CLIFTON RD ATLANTA GA 30322
F. HOFFMAN LAROCHE LTD	GRENZACHERSTRASSE 124 4070 BASEL SWITZERLAND
FATE THERAPEUTICS	12278 SCRIPPS SUMMIT DR SAN DIEGO CA 92121
FATHOM VIDEO, INC.	2261 MARKET STREET 4156 SAN FRANCISCO CA 94114
FISCAL SOLUTIONS LTD.	130 WOOD STREET LONDON EC2V 6DL UNITED KINGDOM
FISHER SCIENTIFIC	1 REAGENT LANE FAIR LAWN NJ 74010
FONDAZIONE TELETHON ETS	VIA VARESE 16B ROMA 00185 ITALY
FU XIN MEDICAL EQUIPMENT CO., LTD.	NO. 96, SEC. 2 REN AI ROAD NEW TAIPEI CITY 24449 TAIWAN
FUNAKOSHI CO., LTD.	9-7 HONGO 2-CHOME BUNKYO-KU TOKYO 113033 JAPAN
GENENTECH, INC.	1 DNA WAY SOUTH SAN FRANCISCO CA 94080
GRAPHITE BIO, INC.	279 E GRAND AVE. SAN FRANCISCO CA 94080
GSL BIOTECH, INC.	225 FRANKLIN STREET FL 26 BOSTON MA 02110
HAVEN AVE., LLC	900 WELCH ROAD SUITE 10 PALO ALTO CA 94304
HUIDAGENE THERAPEUTICS PTD LTD	987 SERANGOON ROAD SINGAPORE
HUIGENE THERAPEUTICS CO, LTD.	FLOOR 2 UNIT 3, BUILDING 5 SHANGHAI CHINA
INGENIUM GROUP, LLC	955 W MISSION AVE ESCONDIDO CA 92025
INSTITUTE FOR SYSTEMS BIOLOGY	401 TERRY AVE SEATTLE WA 98109
INTELLETRACE, INC.	448 IGNACIO BLVD NOVATO CA 94949
JANSEN RESEARCH & DEVELOPMENT LLC	920 ROUTE 202 RARITAN NJ 08869
JEFF MERRICK DBA WIREFORM, LLC	ADDRESS ON FILE
KACTUS BIO, INC.	60 HICKORY DRIVE WALTHAM MA 02451
LAB-A-PORTER LTD.	UNIT 1107 11/F HONG KONG CHINA
LABOSPACE, S.R.L.	VIA VIRGILIO RANZATO 12 MILANO 20128 ITALY
LEADIQ	548 MARKET STREET PMB 20317 SAN FRANCISCO CA 94104
LEIDOS BIOMEDICAL RESEARCH, INC.	1050 BOYLES STREET FREDERICK MD 21702
LG CHEM LTD.	LG TWIN TOWERS 128 YEOUJI-DAERO SEOUL 7336 SOUTH KOREA
LINKEDIN	1000 WEST MAUDE AVENUE SUNNYVALE CA 94085
LINKSQUARES, INC.	60 STATE STREET SUITE 1200 BOSTON MA 02109
LYCIA THERAPEUTICS, INC.	400 EAST JAMIE COURT SUITE 200 SOUTH SAN FRANCISCO CA 94080
MEDICAL UNIVERSITY OF BIALYSTOCK	15-089 BIALYSTOCK POLAND
MERISSA HAMILTON	ADDRESS ON FILE
MODERNATX, INC.	325 BINNEY STREET CAMBRIDGE MA 02142
NATIONAL INSTITUTE OF STANDARDS & TECHNOLOGY	100 BUREAU DRIVE GAITHERSBURG MD 20899
NATIONWIDE CHILDRENS HOSPITAL	RESEARCH INSTITUTE 700 CHILDRENS DR COLUMBUS OH 43205
NEOGENE THERAPEUTICS, INC.	2225 COLORADO AVENUE SANTA MONICA CA 90404
NESTED THERAPEUTICS, INC.	1030 MASS AVENUE SUITE 410 CAMBRIDGE MA 02138
NEUMORA THERAPEUTICS	490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472
NEUROCRINE BIOSCIENCES, INC.	12780 EL CAMINO REAL SAN DIEGO CA 92130
NEUVOCOR PTE. LTD.	3 BIOPOLIS DRIVE SYNAPSE 138623 SINGAPORE

Name	Address
NINE SQUARE THERAPEUTICS CORPORATION	285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
NOVO NORDISK	NOVO ALLÉ BAGSVAERD DK 02880 DENMARK
OPEN AVENUES FOUNDATION	125 WASHINGTON ST. SUITE 204 SALEM MA 01970
ORACLE AMERICA, INC.	2300 ORACLE WAY AUSTIN TX 78741
OXFORD BIOTHEAPEUTICS LTD	SUITE A SECOND FLOOR OXFORD OX4 4GE UNITED KINGDOM
PACIFIC BIOLABS, INC.	551 LINUS PAULING DRIVE HERCULES CA 94547
PACKMAN & ASSOCIATES, INC.	25935 SW STAFFORD RD WILLSONVILLE OR 97070
PACT PHARMA, INC.	2 CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080
PANGEA INC. SA	GUSTAVE-ADOR 20, 1207 GENÈVE SWITZERLAND
PFIZER, INC.	WRD PROCUREMENT 235 EAST 42ND STREET NEW YORK NY 10017
PHILEKOREA TECHNOLOGY, INC.	#B102 WOOLIM LIONS VALLEY SEOUL 08507 KOREA, REPUBLIC OF (SOUTH KOREA)
POSEIDA THERAPEUTICS, INC.	9390 TOWNE CENTER DRIVE SAN DIEGO CA 92121
PRELUDE THERAPEUTICS, INC.	200 POWDER MILL ROAD EXPERIMENTAL STATION E400 / 3213 WILMINGTON DE 19803
PRODUCTIV, INC.	658 HIGH STREET AVE. PALO ALTO CA 94301
PROOF DIAGNOSTICS, INC.	(PINE TREE HEALTH) 700 MAIN STREET NORTH CAMBRIDGE MA 02139
RESEARCH INSTITUTE AT NATIONWIDE	CHILDREN'S HOSPITAL 700 CHILDREN'S DR COLUMBUS OH 43205
ROBERTS, REBECCA	ADDRESS ON FILE
ROCKEND LIMITED	PUDDICOMBE WAY CAMBRIDGE CB2 0AW UNITED KINGDOM
RYVU THERAPEUTICS, S.A.	U.L. STERNBACHA 2 KRAKOW POLAND
SALESFORCE, INC.	415 MISSION STREET 3RD FLOOR SAN FRANCISCO CA 94105
SANA BIOTECHNOLOGY, INC.	188 EAST BLAINE STREET SUITE 400 SEATTLE WA 98102
SAS BIOTIKA	42 ROUTE DU PÉRIMÈTRE ANNECY 74940 FRANCE
SCIENCE EXCHANGE, INC.	2261 MARKET STREET 4759 SAN FRANCISCO CA 94114
SCRATCHPAD	440 N BARRANCA AVE. 9418 COVINA CA 91723-1722
SCRIPPS RESEARCH INSTITUTE FLORIDA	130 SCRIPPS WAY 3C2 JUPITER FL 33458
SERVIER PHARMACEUTICALS LLC	200 PIER FOUR BLVD. BOSTON MA 02210
SIFTED	PO BOX 5237 ATLANTA GA 31107
SNOWFLAKE, INC.	PO BOX 734951 DALLAS TX 75373
SOAPROJECTS, INC.	495 N WHISMAN ROAD SUITE 100 MOUNTAIN VIEW CA 94043
SRI INTERNATIONAL	333 RAVENSWOOD AVE. MENLOW PARK CA 94063
ST. JUDE CHILDRENS RESEARCH HOSPITAL	262 DANNY THOMAS PLACE MEMPHIS TN 38105
SUPREME OPTIMIZATION, LLC	1607 AVENIDA JUAN PONCE DE LEON GM-06 COBIANS PLAZA SAN JUAN PR 00909
YSERCO, INC.	215 FOURIER AVENUE FREMONT CA 94063
TALENTED, INC.	400 SOUTH EL CAMINO REAL SAN MATEO CA 94402
THE REGENTS OF THE UNIVERSITY OF	CALIFORNIA 10920 WILSHIRE BLVD. LOS ANGELES CA 90024
THE TRUSTEES OF THE UNIVERSITY	OF PENNSYLVANIA 2600 CIVIC CENTER BLVD. 9TH FLOOR PHILADELPHIA PA 19104-4310
THE UNIVERSITY OF TEXAS M.D.	ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD. HOUSTON TX 77030
T-KNIFE GMBH	ROBERT-RÖSSLE-STRABE 10 BERLIN 13125 GERMANY
TRINET	ONE PARK PLACE, STE 600 DUBLIN CA 94568-7983
ULTRAGENYX PHARMACEUTICAL, INC.	60 LEVERONI COURT NOVATO CA 94949
UNIVERSAL JANITORIAL	350 PIERCY ROAD SAN JOSE CA 95138
UNIVERSITY OF VERMONT	85 SOUTH PROSPECT STREET WATERMAN BUILDING BURLINGTON VT 05405
VALIDATON SYSTEMS, INC.	988 SAN ANTONIO ROAD PALO ALTO CA 94303
VERTEX PHARMACEUTICALS, INC.	50 NORTHERN AVENUE BOSTON MA 02210
VITA THERAPEUTICS, INC.	801 W BALTIMORE STREET #301 BALTIMORE MD 21205
VIVET THERAPEUTICS, SAS	80 BOULEVARD HAUSSMANN 75008 FRANCE
WATERS TECHNOLOGIES CORP.	34 MAPLE STREET MILLFORD MA 01757
XAIRA THERAPEUTICS, INC.	700 GATEWAY BLVD, 4TH FLOOR SOUTH SAN FRANCISCO CA 94080

Name	Address
XAP THERAPEUTICS, INC.	BABRAHAM RESEARCH CAMPUS MAIA BUILDING (B270) CAMBRIDGE CB22 3AT UNITED KINGDOM
Y.A. ALMOG DIAGNOSITC & MEDICAL	EQUIPMENT, LTD. OREN 4 ST HI-PARK SHOHAM ISRAEL

Total Count: 142

EXHIBIT D

Name	Email
8VC CO-INVEST FUND I, L.P.	nathan@8vc.com; NATHAN@8VC.COM
8VC ENTREPRENEURS FUND I, L.P.	nathan@8vc.com; NATHAN@8VC.COM
8VC FUND I, L.P	nathan@8vc.com; NATHAN@8VC.COM
AAF - SYNTHEGO GROWTH, L.P.	kyle@aaf.vc; KYLE@AAF.VC
AAF II - YASI VENTURES, L.P.	KYLE@AAF.VC; kyle@aaf.vc
APPRENTICE FS, INC.	steven.corey@apprenticefs.com; STEVEN.COREY@APPRENTICEFS.COM
ARAB ANGEL GP I, L.P.	kyle@aaf.vc; KYLE@AAF.VC
DECLARATION CAPITAL PE SPV XLVI LLC	RJACKOWITZ@DECLARATIONPARTNERS.COM
DERYCK C. MAUGHAN REVOCABLE TRUST	ADDRESS ON FILE
DONNELLEY FINANCIAL SOLUTIONS	JAMIE.TOOMBS@DFINSOLUTIONS.COM
EMERGING TECHNOLOGIES FUND II LLC	MARC.WEISS@OFCAP.COM
EMERGING TECHNOLOGIES FUND III LLC	MARC.WEISS@OFCAP.COM
ERNST & YOUNG US LLP	GSS.ACCOUNTSRECEIVABLE@XE02.EY.COM
ERS GENOMICS LIMITED	lcisz@nixonpeabody.com
EXCELSIOR HOLDINGS C2 LLC	PERFORMANCEREPORTING@OLYMPUSVENTURES.COM
GIGAFUND 1, LP	LEGAL@GIGAFUND.COM
GRANT THORNTON LLP	CASH@US.GT.COM; CHRIS.STATHOPOULOS@US.GT.COM
LESLIE ENTERPRISES LP	MLESLIE@LESLIEVENTURES.COM
LUMA BIO-IT SPV, L.P.	legal@8vc.com; LEGAL@8VC.COM
LUMA BIO-IT SPV-A, L.P.	legal@8vc.com; LEGAL@8VC.COM
MENLO VENTURES XI, L.P.	FINANCE@MENLOVC.COM
MERRICK, KAY E.	ADDRESS ON FILE
MMEF XI, L.P.	FINANCE@MENLOVC.COM
MORROW-MEADOWS CORPORATION	INFO@MORROW-MEADOWS.COM
NIXON PEABODY LLP	lcisz@nixonpeabody.com
OFFICE OF THE UNITED STATES TRUSTEE	jon.lipshie@usdoj.gov; megan.seliber@usdoj.gov
OFFIT KURMAN, P.A.	brian.mclaughlin@offitkurman.com
PACHULSKI STANG ZIEHL & JONES LLP	JONeill@pszjlaw.com
PERCEPTIVE CR. HOLDINGS III LP	JNewton@mofo.com; MRussell@mofo.com; jkrenn@mofo.com; dmckenzie@mofo.com; wwinsett@mofo.com; iguevrekian@mofo.com
PERCEPTIVE CREDIT HOLDINGS III, LP	csamis@potteranderson.com; bhaywood@potteranderson.com; sforshay@potteranderson.com
PROPHARMA GROUP HOLDINGS, LLC	TOM.HUNTER@PROPHARMAGROUP.COM
PRS, LLC	NP@PSOROS.COM
RNA SPV LLC	RAJGARG10@AOL.COM
SECURITIES & EXCHANGE COMMISSION	CHAIR@SEC.GOV;CommissionerPeirce@sec.gov; CommissionerCrenshaw@sec.gov; CommissionerUyeda@sec.gov
SECURITIES & EXCHANGE COMMISSION	CHAIR@SEC.GOV;CommissionerPeirce@sec.gov; CommissionerUyeda@sec.gov
TN DEPT OF REVENUE	AGBankDelaware@ag.tn.gov
TRUEBRIDGE DIRECT FUND L.P.	MWILLIAMS@TRUEBRIDGECAPITAL.COM
WEIL, GOTSHAL & MANGES LLP	MELISSA.APPENRODT@WEIL.COM
WELLINGTON HADLEY HARBOR MASTER INVESTORS	TMKANE@WELLINGTON.COM

Total Count: 62